Intarcia Therapeutics, a US-based biopharmaceutical firm whose name is derived from the Latin for insert, has nearly doubled the equity it has raised over the past 15 years with its latest $160m round.

Intarcia said its combined $160m sale of shares and $50m debt placement was “the largest sum to be raised by a private biotechnology company in at least 25 years”.

Venture capital firms New Enterprise Associates (NEA), New Leaf Venture Partners, Venrock, Alta Partners and Foresite Capital, secondaries…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?